The Federal Circuit affirmed that Arbutus Biopharma’s patent on stable nucleic acid-lipid particles (SNALPs) with non-lamellar morphology was inherently anticipated by an earlier Arbutus patent, holding that when the same formulation process disclosed in both patents naturally produces the cla
The Federal Circuit affirmed willful infringement of Ironburg’s video game controller patent by Valve’s Steam Controller, while vacating and clarifying the standard for IPR estoppel — holding that the patent owner, not the petitioner, bears the burden of proving estoppel applies.
The Federal Circuit reversed the PTAB’s finding of no obviousness, holding that when two prior art references address the same technical problem and one provides a known technique for solving it, a skilled artisan would be motivated to combine them—the Board’s contrary conclusion contrad
The Federal Circuit revived Apple’s Administrative Procedure Act challenge to the USPTO’s Fintiv policy, under which the PTAB discretionarily denies institution of inter partes reviews when parallel district court litigation is proceeding, allowing the challenge to be heard on its merits
The Federal Circuit affirmed the PTAB’s ruling that the University of Minnesota’s antiviral drug patent—directed to phosphoramidate prodrugs of nucleoside derivatives—lacked adequate written description support for its broad genus claims, because the patent’s specification disclose
The Federal Circuit affirmed the delisting of Jazz Pharmaceuticals’ REMS system patent from the FDA Orange Book, holding that a patent claiming a drug distribution and monitoring system — rather than the drug itself or a method of using it — is ineligible for Orange Book listing.
The Federal Circuit affirmed that Minerva Surgical’s demonstration of 15 fully functional endometrial ablation device prototypes at an industry trade show—more than a year before the patent’s priority date—triggered the public use bar of pre-AIA § 102(b) and invalidated the asserted pate
The Federal Circuit affirmed that patent claims directed to isolated nicotinamide riboside (NR)—a form of vitamin B3 found naturally in cow’s milk—are directed to a natural phenomenon and ineligible under § 101, because the claims effectively read on milk with only the isolation step as a diff
The Federal Circuit held that the USPTO Director’s authority to review PTAB decisions under the Arthrex remedy is not constrained by the IPR statutory deadlines, and that the Appointments Clause does not guarantee patent owners a right to timely Director rehearing.
The Federal Circuit affirmed that Personalized Media Communications’ patent covering digital rights management technology is unenforceable for prosecution laches, voiding a $308 million jury verdict against Apple, after finding PMC engaged in unreasonable and unexplained delays in prosecuting